1
|
Houvenaeghel G, Cohen M, Dammacco MA, D'Halluin F, Regis C, Gutowski M, Acker O, Fournier M, Bannier M, Lusque A, Jouve E. Prophylactic nipple-sparing mastectomy with immediate breast reconstruction: results of a French prospective trial. Br J Surg 2021; 108:296-301. [PMID: 33793719 DOI: 10.1093/bjs/znaa082] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 10/14/2020] [Indexed: 12/25/2022]
Abstract
BACKGROUND Nipple-sparing mastectomy (NSM) with immediate breast reconstruction (IBR) is used increasingly when performing a prophylactic mastectomy. Few prospective studies have reported on complication rates. This complementary trial to the French prospective multicentre MAPAM trial aimed to evaluate the nipple-areola complex (NAC) necrosis rate in prophylactic NSM with IBR. METHODS Patient characteristics and surgical data were recorded. Morbidity after prophylactic NSM with a focus on NAC necrosis was analysed. RESULTS Among 59 women undergoing prophylactic NSM, 19 (32 per cent) of the incisions were partly on the NAC. Reconstructions were performed with 46 definitive implants and 13 expanders. The crude rate of postoperative complications was 25 per cent (15 patients). Complete NAC necrosis was reported in two women (3 per cent) and partial or total necrosis in nine (15 per cent). No NAC resection was necessary. Median BMI was lower in women with total or partial NAC necrosis compared with the others (20.0 versus 21.3 kg/m2 respectively; P = 0.034). CONCLUSION Results of this prospective study confirm that prophylactic NSM with IBR is associated with a low risk of total NAC necrosis.
Collapse
Affiliation(s)
- G Houvenaeghel
- Department of Surgical Oncology, Paoli Calmettes Institute and Centre de Recherche en Cancerérologie de Marseille (CRCM), Aix-Marseille University, Marseille, France
| | - M Cohen
- Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France
| | - M A Dammacco
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - F D'Halluin
- Surgery Department, L'Etablissement Rennais du Sein, Centre Hospitalier Privé St Grégoire, St Grégoire, France
| | - C Regis
- Department of Surgical Oncology, Centre Oscar Lambret, Lille, France
| | - M Gutowski
- Department of Surgical Oncology, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France
| | - O Acker
- Surgery Department, Pôle Santé Léonard de Vinci, Chambray les Tours, France
| | - M Fournier
- Department of Surgical Oncology, Institut Bergonie, Bordeaux, France
| | - M Bannier
- Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France
| | - A Lusque
- Department of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
| | - E Jouve
- Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
| | | |
Collapse
|
2
|
Moisset X, Bouhassira D, Couturier JA, Alchaar H, Conradi S, Delmotte MH, Lantéri-Minet M, Lefaucheur JP, Mick G, Piano V, Pickering G, Piquet E, Regis C, Salvat E, Attal N. Traitements pharmacologiques et non pharmacologiques de la douleur neuropathique : une synthèse des recommandations françaises. ACTA ACUST UNITED AC 2020. [DOI: 10.3166/dea-2020-0113] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Les douleurs neuropathiques (DN) restent très difficiles à soulager. Plusieurs recommandations ont été proposées au cours de ces dernières années, mais aucune n’a pris en compte à ce jour l’ensemble des approches thérapeutiques disponibles. Nous avons réalisé une revue systématique portant sur toutes les études concernant le traitement des DN périphériques et centrales de l’adulte et de l’enfant, publiées jusqu’en janvier 2018 et avons évalué la qualité des études et le niveau de preuve des traitements au moyen du système GRADE. Les principaux critères d’inclusion étaient l’existence d’une DN chronique (≥ 3 mois), une méthodologie contrôlée et randomisée, un suivi supérieur ou égal à trois semaines, un nombre de patients supérieur ou égal à dix par groupe et une évaluation en double insu pour les traitements pharmacologiques. Sur la base du GRADE, nous recommandons en première intention les antidépresseurs inhibiteurs mixtes de recapture des monoamines (duloxétine et venlafaxine), les antidépresseurs tricycliques, la gabapentine pour toute DN, et les emplâtres de lidocaïne 5 % et la stimulation électrique transcutanée pour les DN périphériques localisées. Nous recommandons en deuxième intention la prégabaline, le tramadol (avec les précautions d’emploi afférentes aux opioïdes) et certaines associations pharmacologiques (antidépresseurs et gabapentine ou prégabaline) pour toute DN, et les patchs de haute concentration de capsaïcine (8 %) et la toxine botulique de type A (en milieu spécialisé) pour les DN périphériques localisées. Nous recommandons en troisième intention la stimulation magnétique transcrânienne répétitive à haute fréquence du cortex moteur (en milieu spécialisé) et les opioïdes forts (en l’absence d’alternative et en respectant les précautions d’emploi afférentes aux opioïdes) pour toute douleur neuropathique, et la stimulation médullaire pour les douleurs radiculaires chroniques postchirurgicales et la polyneuropathie diabétique douloureuse. La psychothérapie (thérapie cognitivocomportementale et thérapie de pleine conscience) peut être recommandée en deuxième intention en association avec les traitements précédents.
Collapse
|
3
|
Regis C, Bosc R, Le Deley MC, Hannebicque K, Chauvet MP, Boulanger L. Impact of the COVID -19 pandemic on the organisation of breast reconstruction in France. J Plast Reconstr Aesthet Surg 2020; 74:644-710. [PMID: 32978109 PMCID: PMC7833913 DOI: 10.1016/j.bjps.2020.08.114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 08/18/2020] [Indexed: 11/29/2022]
Affiliation(s)
- C Regis
- Department of Surgery, Centre Oscar Lambret, 3 rue F.-Combemale, 59020 Lille cedex, France.
| | - R Bosc
- Department of Plastic, Reconstructive, Aesthetic and maxillofacial Surgery, Henry Mondor Hospital, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil France
| | - M C Le Deley
- Biostatisitcs Unit, Centre Oscar Lambret, 3 rue F.-Combemale, 59020 Lille cedex, France
| | - K Hannebicque
- Department of Surgery, Centre Oscar Lambret, 3 rue F.-Combemale, 59020 Lille cedex, France
| | - M P Chauvet
- Department of Surgery, Centre Oscar Lambret, 3 rue F.-Combemale, 59020 Lille cedex, France
| | - L Boulanger
- Department of Surgery, Centre Oscar Lambret, 3 rue F.-Combemale, 59020 Lille cedex, France
| |
Collapse
|
4
|
Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, Lanteri-Minet M, Lefaucheur JP, Mick G, Piano V, Pickering G, Piquet E, Regis C, Salvat E, Attal N. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris) 2020; 176:325-352. [PMID: 32276788 DOI: 10.1016/j.neurol.2020.01.361] [Citation(s) in RCA: 123] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Accepted: 01/07/2020] [Indexed: 02/08/2023]
Abstract
Neuropathic pain remains a significant unmet medical need. Several recommendations have recently been proposed concerning pharmacotherapy, neurostimulation techniques and interventional management, but no comprehensive guideline encompassing all these treatments has yet been issued. We performed a systematic review of pharmacotherapy, neurostimulation, surgery, psychotherapies and other types of therapy for peripheral or central neuropathic pain, based on studies published in peer-reviewed journals before January 2018. The main inclusion criteria were chronic neuropathic pain for at least three months, a randomized controlled methodology, at least three weeks of follow-up, at least 10 patients per group, and a double-blind design for drug therapy. Based on the GRADE system, we provide weak-to-strong recommendations for use and proposal as a first-line treatment for SNRIs (duloxetine and venlafaxine), gabapentin and tricyclic antidepressants and, for topical lidocaine and transcutaneous electrical nerve stimulation specifically for peripheral neuropathic pain; a weak recommendation for use and proposal as a second-line treatment for pregabalin, tramadol, combination therapy (antidepressant combined with gabapentinoids), and for high-concentration capsaicin patches and botulinum toxin A specifically for peripheral neuropathic pain; a weak recommendation for use and proposal as a third-line treatment for high-frequency rTMS of the motor cortex, spinal cord stimulation (failed back surgery syndrome and painful diabetic polyneuropathy) and strong opioids (in the absence of an alternative). Psychotherapy (cognitive behavioral therapy and mindfulness) is recommended as a second-line therapy, as an add-on to other therapies. An algorithm encompassing all the recommended treatments is proposed.
Collapse
Affiliation(s)
- X Moisset
- Université Clermont Auvergne, Inserm, Neuro-Dol, 63000 Clermont-Ferrand, France; CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France.
| | - D Bouhassira
- INSERM U987, CETD, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France; Université Versailles - Saint-Quentin-en-Yvelines, Versailles, France
| | - J Avez Couturier
- Service de Neuropédiatrie, Consultation Douleur Enfant, CIC-IT 1403, CHU de Lille, Lille, France
| | - H Alchaar
- 73, boulevard de Cimiez, Nice, France
| | - S Conradi
- CETD, CHRU de Nancy, Vandœuvre-lès-Nancy, France
| | - M H Delmotte
- GHU, Paris site Ste-Anne, Structure Douleurs, 1, rue Cabanis, Paris 14, France
| | - M Lanteri-Minet
- Université Clermont Auvergne, Inserm, Neuro-Dol, 63000 Clermont-Ferrand, France; Département d'Évaluation et Traitement de la Douleur, Centre Hospitalier Universitaire (CHU) de Nice, Fédération Hospitalo-Universitaire InovPain, Université Côte d'Azur, Nice, France
| | - J P Lefaucheur
- EA 4391, Faculté de Médecine, Université Paris Est Créteil, Créteil, France; Service de Physiologie, Explorations Fonctionnelles, Hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France
| | - G Mick
- Centre d'Évaluation et Traitement de la Douleur du Voironnais, Centre Hospitalier de Voiron, Laboratoire P2S, Université de Lyon, Lyon, France
| | - V Piano
- Centre Hospitalier de Draguignan, Service Algologie 4(e), route de Montferrat, 83007 Draguignan cedex, France
| | - G Pickering
- Université Clermont Auvergne, Inserm, Neuro-Dol, 63000 Clermont-Ferrand, France; Clinical Pharmacology Department, CPC/CIC Inserm 1405, University Hospital CHU, Clermont-Ferrand, France
| | - E Piquet
- Département d'Évaluation et Traitement de la Douleur, Centre Hospitalier Universitaire (CHU) de Nice, Fédération Hospitalo-Universitaire InovPain, Université Côte d'Azur, Nice, France
| | - C Regis
- CETD, CHU Montpellier, Montpellier, France
| | - E Salvat
- Centre d'Évaluation et de Traitement de la Douleur, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France
| | - N Attal
- INSERM U987, CETD, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France; Université Versailles - Saint-Quentin-en-Yvelines, Versailles, France
| |
Collapse
|
5
|
Hannebicque K, Renaudeau C, Giard S, Regis C, Boulanger L, Bogart E, Le Deley MC, Ceugnart L, Chauvet MP. Abstract P5-16-04: Evaluation of autologous fat grafting local morbidity (fat necrosis and biopsy rates) in breast reconstruction after breast cancer: A retrospective study on 257 patients in Oscar Lambret Center. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background.Autologous fat grafting (AFG) is a widely used procedure in breast reconstruction after breast cancer. Indications are in constant increase but there is a lack of dataabout global morbidity, especially fat necrosis and management of local complications. The purpose of this study was to evaluate the complications rate in term of abnormal clinical examination or imaging and the proportion of additional explorations.
Methods. We retrospectively reviewed the computerized files of consecutive patients who underwent AFG for breast reconstruction after breast cancer or for preventive surgery and aesthetic sequelae after lumpectomy in the Oscar Lambret center between January 2013 and December 2016. Fat grafts were harvested with a fat trap then processed and injected according the Coleman technique. We collected demographics, operative details, local complications, incidence of palpable masses and/or suspicious breast imaging findings leading to additional explorations (breast imaging or biopsy), and locoregional cancer recurrence. Descriptive statistics were generated.
Results. Over a 4-year period, 257 women underwent autologous fat grafting for breast reconstruction and aesthetic sequelae after lumpectomy. Their mean age was 50 years [range 28-75], the mean BMI was 25 [range 18-44], 26% (n=66) were smoking and 74% (n=190) underwent radiotherapy. A total of 303 breasts were operated by 270 mastectomies (89%) or33 lumpectomies (11%). The reconstruction was delayed in 63% (n=171) and the main techniques used were breast implant (44%, n=119) and autologous latissimus dorsi (31%, n=84). The mean number of fat grafting procedures was 1,9 per patient [range 1-7] with a mean volume of 181 mL [range 30-535]. The mean time interval between cancer diagnosis and first fat graft session was 56 months [range 3-285], and the follow-up ranged from 0 to 51 months (mean=16). The prevalence of donor site complications was 6% (n=16) and infections was 2% (n=5). Sixty six (25,6%) patients had a clinically palpable lesion and 54 (21%) underwent additional imagings, mostly by ultrasounds (53 patients, 98%) except the usual follow-up. Twenty one biopsies (8%) were performed and showed 16 benign results (76,2%) and 5 malignant results (23,8%) leading to 6,2% of fat necrosis and 1,9% of locoregional recurrence after AFG in our study.Tobacco (p=0.45), BMI (p=0.95), radiotherapy (p=0.56) and amount of fat grafted ( p=0.09) didn't appear to be risk factors for fat necrosis.
Conclusions. A good knowledge of local complications by surgeons and radiologists enables to avoid systematic and repeated further imaging explorations. Multicentric, prospective studies with long term follow up and evaluation of patients reported outcomes are needed to evaluate anxiety generated by biopsies and costs generated by repeated imagings.
Key words: autologous fat grafting, breast cancer, local morbidity, fat necrosis.
Citation Format: Hannebicque K, Renaudeau C, Giard S, Regis C, Boulanger L, Bogart E, Le Deley M-C, Ceugnart L, Chauvet M-P. Evaluation of autologous fat grafting local morbidity (fat necrosis and biopsy rates) in breast reconstruction after breast cancer: A retrospective study on 257 patients in Oscar Lambret Center [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
| | | | - S Giard
- Oscar Lambret Center, Lille, Nord, France
| | - C Regis
- Oscar Lambret Center, Lille, Nord, France
| | | | - E Bogart
- Oscar Lambret Center, Lille, Nord, France
| | | | - L Ceugnart
- Oscar Lambret Center, Lille, Nord, France
| | | |
Collapse
|
6
|
Plantamp C, Henri H, Andrieux T, Regis C, Mialdea G, Dray S, Gibert P, Desouhant E. Phenotypic plasticity in the invasive pest Drosophila suzukii: activity rhythms and gene expression in response to temperature. J Exp Biol 2019; 222:jeb.199398. [DOI: 10.1242/jeb.199398] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Accepted: 06/07/2019] [Indexed: 11/20/2022]
Abstract
Phenotypic plasticity may contribute to the invasive success of an alien species in a new environment. A higher plastic species may survive and reproduce in more diverse environments, thereby supporting establishment and colonization. We focused on plasticity in the circadian rhythm of activity, which can favour species coexistence in invasion, for the invasive species Drosophila suzukii, which is expected to be a weaker direct competitor than other Drosophila species of the resident community. We compared between the invasive D. suzukii and the resident D. melanogaster the circadian rhythms of the locomotor activity in adults and the expression of clock genes in response to temperature. We showed that D. suzukii is active in a narrower range of temperatures than D. melanogaster and that the activities of both species overlap during the day, regardless of the temperature. Both species are diurnal and exhibit rhythmic activity at dawn and dusk, with a much lower activity at dawn for D. suzukii females. Our results showed that the timeless and clock genes are good candidates to explain the plastic response that is observed in relation to temperature. Overall, our results suggest that thermal phenotypic plasticity in D. suzukii activity is not sufficient to explain the invasive success of D. suzukii and calls for testing other hypotheses, such as the release of competitors and/or predators.
Collapse
Affiliation(s)
- C. Plantamp
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - H. Henri
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - T. Andrieux
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - C. Regis
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - G. Mialdea
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - S. Dray
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - P. Gibert
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| | - E. Desouhant
- Université de Lyon, 69000 Lyon, Université Claude Bernard Lyon 1, CNRS, VetAgro Sup, INRIA, Laboratoire de Biométrie et Biologie Evolutive, UMR 5558, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
| |
Collapse
|
7
|
Quemener J, Wallet J, Boulanger L, Hannebicque K, Giard S, Chauvet MP, Regis C. Abstract P4-13-07: Determinants in decision-making process of breast reconstruction in women over 65 years old. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-13-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is the most common cancer among European women with 54,000 new cases in France in 2015. Nearly 47% of these cancers are diagnosed in women aged 65 and over. Mastectomy is still needed in 30% of cases, resulting in significant physical and psychological consequences. Breast reconstruction (BR) can reduce the effects of surgical treatment and improve quality of life. However, less than 20% of women choose BR in France. This number drops to 6% for patients over 65 years old. The objective of the study was to find the factors influencing the decision-making process for attempting breast reconstruction in women who are over 65.
Methods: We included retrospectively all patients over 65 years old who had an immediate or delayed breast reconstruction in our Cancer Center from January 2006 to July 2016. We set up a control group matching them with patients treated by mastectomy during the same period who did not choose BR. The matched-pair criteria were age, TNM stage and performans status, obtained from multidisciplinary consultation meeting database. We mailed to all patients a specially-designed questionnaire inspired by the BREAST-Q aimed at assessing the medical information that was delivered to them about BR and the reasons to choose or not choose reconstruction. The qualitative and quantitative results were analyzed. The two groups were compared using Chi-square, Fisher's exact, Mann-Whitney, and Student t test.
Results: Among 134 patients, 103 (77%) completed the questionnaire. Dedicated information on BR before the mastectomy was provided more frequently to patients who had BR (91.7% vs 66.7% p=0.008). Forty-one percent of patients sought out sources of information other than their surgeon (other physicians, friends, other patients, the internet – no significant differences between the two groups, p=0.1). The three most important persons influencing the decision-making process were first the patient's surgeon, second the patient's husband, and third her general practitioner (GP). These people were more often in favor of reconstruction in the BR group than in the mastectomy group (respectively, 94.5% vs 22.9% p<0.001; 65.4% vs 7.1 % p<0.001; and 64.2% vs 19.4%, p<0.001). Women judged that their age was an obstacle to reconstruction at the rate of 66.7% for the mastectomy group and at the rate of 3.8% in the BR group (p= 0.001). None of the women reported that her surgeon considered her age to be an obstacle for breast reconstruction. Women in the mastectomy group reported more fears about reconstruction than the women in the BR group (p< 0.001). Patients had less opportunity to talk about their fears with their surgeon in the mastectomy group (19.4% vs 66.1% p<0.001).
Conclusions: Providing dedicated information at the time of initial support is crucial in the choice of BR for women over 65. Patients' surgeons played a central role in the decision, but their GPs and husbands also provided important input. This dedicated information should help women over 65 to conclude that their age should not be a limiting factor for the decision to attempt breast reconstruction.
Citation Format: Quemener J, Wallet J, Boulanger L, Hannebicque K, Giard S, Chauvet MP, Regis C. Determinants in decision-making process of breast reconstruction in women over 65 years old [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-13-07.
Collapse
Affiliation(s)
| | - J Wallet
- Centre Oscar Lambret, Lille, France
| | | | | | - S Giard
- Centre Oscar Lambret, Lille, France
| | | | - C Regis
- Centre Oscar Lambret, Lille, France
| |
Collapse
|
8
|
Regis C, Le J, Le Teuff G, Cucchi M, Boulanger L, Hannebicque K, Giard S, Chauvet MP, Quemenr J, Ledeley MC. Abstract P4-13-03: Variations in breast reconstruction rate in France according to patient and site characteristics: A nationwide retrospective study of nearly 20,000 patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-13-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast reconstruction (BR) for women who undergo mastectomy for cancer offers psychological benefits and improves quality of life. However its use remains limited, especially for women over 65 years, with a large degree of international variation. The aim of this study was to find out factors influencing the surgical decision of BR in France where cancer related healthcare costs are fully reimbursed.
Methods: We used the French medico-administrative database to identify all primary mastectomies for breast carcinoma in 2012 and studied the rate of immediate (IR) or delayed breast reconstruction (DR) up to December 2015.
Variations of BR rates were evaluated according to
- patient age, social deprivation index,
- profile of the hospital where the mastectomy was performed: type of hospital (cancer center, CC; university hospitals, UH; private, PrivH; or public, PubH), and hospital activity (surgical acts for breast cancer in 2012);
- disparities across administrative regions in terms of number of CC or UH, number of plastic surgeons, gynecologist-obstetrician surgeons and general surgeons in the region.
A hierarchical three-level logistic regression was used with SAS GLIMMIX to model the probability of BR taking into account clustering of observations (patients in hospitals, hospitals in regions). Splines were used to explore the functional form of the relationship between continuous variables and BR rate. Akaike information criterion was used for model selection.
Results: Among the 19,466 women who had a mastectomy in 2012, 5,328 (27.4%) subsequently had a BR: IR for 13.7% and DR for 13.7%. The BR rate significantly varied with age (p<0.0001), resulting in a much smaller BR rate in patients older than 65 compared to younger (7.5% vs 42.1%, p<0.0001). In case of BR, IR was more frequent than DR in older patients (66% of BR), whereas both were equally balanced before 65. BR rates decreased with increasing social deprivation index (from 32.7% to 21.5%, from the first to the fourth quartile of the distribution). BR rates significantly varied according to hospital type (35.0% in CC, 29.8% in UH, 25.9% in PrivH and 18.6% in PubH). BR rates were significantly lower in small activity hospital (varying from 13.4% in hospital with <=50 annual breast surgery to 35.1% in hospitals with >500), especially in older patients (varying from 3.1% to 10.3%). We also observed important heterogeneity of BR rates across administrative regions, but these variations were not explained by the number of CC or UH, the number of plastic surgeons, the number of gynecologist-obstetrician surgeons or the number of general surgeons in the region. In multivariate analysis, BR rate was significantly associated with age (p<0.0001), social deprivation index (p<0.0001), type of hospital (p=0.002) and hospital activity (p<0.0001), with persistent heterogeneity across administrative regions.
Conclusions: We identified substantial variations in BR rates across the French hospitals. Controlling for possible confounders, older patients have less breast reconstruction. This apparent heterogeneity can be part of women choice, however it suggests unequal access to high quality procedures for older women with breast cancer.
Citation Format: Regis C, Le J, Le Teuff G, Cucchi M, Boulanger L, Hannebicque K, Giard S, Chauvet M-P, Quemenr J, Ledeley M-C. Variations in breast reconstruction rate in France according to patient and site characteristics: A nationwide retrospective study of nearly 20,000 patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-13-03.
Collapse
Affiliation(s)
- C Regis
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - J Le
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - G Le Teuff
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - M Cucchi
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - L Boulanger
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - K Hannebicque
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - S Giard
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - M-P Chauvet
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - J Quemenr
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| | - M-C Ledeley
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Gustave Roussy, Villejuif, France
| |
Collapse
|
9
|
Houvenaeghel G, Cohen M, Raro P, De Troyer J, Tunon De Lara C, Guimbergues P, Gauthier T, Faure C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Di Beo V, Lambaudie E, Tallet A, Boher JM. Abstract P3-01-02: Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: Axillary dissection versus no axillary dissection in patients with involved sentinel node. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Three randomized trials have concluded at non inferiority of omission of complementary axillary lymph node dissection (cALND) for patients with involved sentinel node (SN). However, we can outline strong limitations of these trials to validate this attitude with a high scientific level. We designed the SERC randomized trial to compare outcomes in patients with SN involvement treated with ALND or no further axillary treatment. The aim of this study was to analyze results of the first 1000 patients included.
Patients and Methods: SERC trial is a multicenter non-inferiority phase 3 trial. Multivariate logistic regression analysis was used to identify independent factors associated with adjuvant chemotherapy administration and non-sentinel node (NSN) involvement.
Results : Of the 963 patients included in the analysis set, 478 were randomized to receive cALND and 485 SLNB alone. All patient demographics and tumor characteristics were balanced between the two arms. SN ITC was present in 6.3% patients (57/903), micro metastases in 33.0% (298), macro metastases in 60.7% (548) and 289 (34.2%) were non eligible to Z0011 trial criteria.
Whole breast or chest wall irradiation was delivered in 95.9% (896/934) of patients, adjuvant chemotherapy in 69.5% (644/926), endocrine therapy in 89.6% (673/751) and the proportions were similar in the two arms. The overall rate of positive NSN was 19% (84/442) for patients with cALND. Crude rates of positive NSN according to SN status were 4.5% for ITC (1/22), 9.5% for micro metastases (13/137), 23.9% for macro metastases (61/255) and were respectively 29.36% (64/218), 9.33% (7/75) and 7.94% (10/126) when chemotherapy was administered after cALND, before cALND and for patients without chemotherapy.
Conclusion: The main objective of SERC trial is to demonstrate non inferiority of cALND omission. A strong interaction between timing of cALND and chemotherapy with positive NSN rate was observed.
Citation Format: Houvenaeghel G, Cohen M, Raro P, De Troyer J, Tunon De Lara C, Guimbergues P, Gauthier T, Faure C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo P-E, Di Beo V, Lambaudie E, Tallet A, Boher J-M. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: Axillary dissection versus no axillary dissection in patients with involved sentinel node [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-01-02.
Collapse
Affiliation(s)
- G Houvenaeghel
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - M Cohen
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - P Raro
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - J De Troyer
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - C Tunon De Lara
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - P Guimbergues
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - T Gauthier
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - C Faure
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - V Vaini-Cowen
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - S Lantheaume
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - C Regis
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - E Darai
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - V Ceccato
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - G D'Halluin
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - F Del Piano
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - R Villet
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - E Jouve
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - B Beedassy
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - P Theret
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - P Gabelle
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - C Zinzindohoue
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - P Opinel
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - C Marsollier-Ferrer
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - C Dhainaut-Speyer
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - P-E Colombo
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - V Di Beo
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - E Lambaudie
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - A Tallet
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| | - J-M Boher
- Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France; Polyclinique Urbain V, Avignon, France; Institut Bergonie, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; CHU Limoges, Limoges, France; Centre Léon Bérard, Lyon, France; Clinique d'Aix, Aix-en-Provence, France; Hopital Privé Drome Ardèche - Clinique Pasteur, Guilherand Granges, France; Centre Oscar Lambret, Lille, France; Hôpital Tenon, Paris, France; Institut Jean Godinot, Reims, France; Centre Clinical, Angoulème, France; Hôpitaux du Leman, Thonon, France; Groupe Hospitalier des Diaconesses, Paris, France; Institut Universitaire du Cancer, Toulouse, France; Hôpital Sainte Musse (CHITS), Toulon, France; CHU Amiens-Picardie - Hopital Nord, Amiens, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Clinique Clemenville, Montpellier, France; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France; CHRU Nimes, Nimes, France; GCS Recherche et Innovation, Sainte
| |
Collapse
|
10
|
Chretien S, Kotecki N, Wallet J, Desmedt C, Mailliez A, Regis C, Pasquier D, Robin YM, Bonneterre J. Pathological characteristics and prognosis of a cohort of 57 patients (pts) with de novo oligometastatic breast cancer (OMBC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Girard M, Regis C. Healthcare in Nunavik, Canada: Basis for a Mixed Method Study. Ann Glob Health 2017. [DOI: 10.1016/j.aogh.2017.03.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
12
|
Vanhems P, Baghdadi Y, Roche S, Bénet T, Regis C, Lina B, Robert O, Voirin N, Ecochard R, Amour S. Influenza vaccine effectiveness among healthcare workers in comparison to hospitalized patients: A 2004-2009 case-test, negative-control, prospective study. Hum Vaccin Immunother 2016; 12:485-90. [PMID: 26327520 DOI: 10.1080/21645515.2015.1079677] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
The objective of this study was to calculate Vaccine Effectiveness (VE) in healthcare workers (HCW) and to compare VE between patients and HCW. A case-control investigation based on the prospective study was conducted between 2004 and 2009 in a teaching hospital. All HCW with influenza-like illness (ILI) from participating units (n = 24) were included, and vaccination status was characterized by interview. A total of 150 HCW presented ILI; 130 (87%) were female, 27 (18%) were positive for influenza, and 42 (28%) were vaccinated. Adjusted VE was 89% (95% CI 39 to 98). Among patients, adjusted VE was 42% (95% CI -39 to 76). The difference of VE (VEhcw - VEpat) was 46.15% (95% CI 2.41 to 144). The VE ratio (VEhcw / VEpat) was 2.09 (95% CI -1.60 to 134.17). Influenza VE differed between HCW and patients when the flu season was taken into account. This finding confirms the major impact of host determinants on influenza VE.
Collapse
Affiliation(s)
- P Vanhems
- a Service d'Hygiène; Epidémiologie et Prévention; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France.,b Laboratoire d'Epidémiologie et Santé Publique; Université Claude Bernard Lyon 1; Université de Lyon ; Lyon , France
| | - Y Baghdadi
- b Laboratoire d'Epidémiologie et Santé Publique; Université Claude Bernard Lyon 1; Université de Lyon ; Lyon , France
| | - S Roche
- c Service de Biostatistique; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France.,d Equipe Biostatistique-Santé; Center National de la Recherche Scientifique-Unité Mixte de Recherche 5558; Université Claude Bernard Lyon 1; Université de Lyon ; Villeurbanne , France
| | - T Bénet
- a Service d'Hygiène; Epidémiologie et Prévention; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France
| | - C Regis
- b Laboratoire d'Epidémiologie et Santé Publique; Université Claude Bernard Lyon 1; Université de Lyon ; Lyon , France
| | - B Lina
- e Centre de Biologie et Pathologie Est; Center National de référence des virus influenza région Sud; Groupement Hospitalier Est; Hospices Civils de Lyon ; Bron , France.,f Département de Virologie ; Université Lyon 1; Université de Lyon ; Bron , France
| | - O Robert
- g Service de médecine Préventive du Personnel; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France
| | - N Voirin
- a Service d'Hygiène; Epidémiologie et Prévention; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France
| | - R Ecochard
- c Service de Biostatistique; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France.,d Equipe Biostatistique-Santé; Center National de la Recherche Scientifique-Unité Mixte de Recherche 5558; Université Claude Bernard Lyon 1; Université de Lyon ; Villeurbanne , France
| | - S Amour
- a Service d'Hygiène; Epidémiologie et Prévention; Groupement hospitalier Edouard Herriot; Hospices Civils de Lyon ; Lyon , France
| |
Collapse
|
13
|
Kakkos A, Bresson L, Hudry D, Cousin S, Lervat C, Bogart E, Meurant JP, El Bedoui S, Decanter G, Hannebicque K, Regis C, Hamdani A, Penel N, Tresch-Bruneel E, Narducci F. Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients. Eur J Surg Oncol 2016; 43:689-695. [PMID: 27889197 DOI: 10.1016/j.ejso.2016.10.020] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Revised: 10/05/2016] [Accepted: 10/21/2016] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Totally implantable venous access port systems are widely used in oncology, with frequent complications that sometimes necessitate device removal. The aim of this study is to investigate the impact of the time interval between port placement and initiation of chemotherapy and the neutropenia-inducing potential of the chemotherapy administered upon complication-related port removal. PATIENTS AND METHODS Between January 2010 and December 2013, 4045 consecutive patients were included in this observational, single-center prospective study. The chemotherapy regimens were classified as having a low (<10%), intermediate (10-20%), or high (>20%) risk for inducing neutropenia. RESULTS The overall removal rate due to complications was 7.2%. Among them, port-related infection (2.5%) and port expulsion (1%) were the most frequent. The interval between port insertion and its first use was shown to be a predictive factor for complication-related removal rates. A cut-off of 6 days was statistically significant (p = 0.008), as the removal rate for complications was 9.4% when this interval was 0-5 days and 5.7% when it was ≥6 days. Another factor associated with port complication rate was the neutropenia-inducing potential of the chemotherapy regimens used, with removal for complications involved in 5.5% of low-risk regimens versus 9.4% for the intermediate- and high-risk regimens (p = 0.003). CONCLUSION An interval of 6 days between placement and first use of the port reduces the removal rate from complications. The intermediate- and high-risk for neutropenia chemotherapy regimens are related to higher port removal rates from complications than low-risk regimens.
Collapse
Affiliation(s)
- A Kakkos
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France.
| | - L Bresson
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - D Hudry
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - S Cousin
- Department of Medical Oncology, Centre Régional de Lutte Contre le Cancer Institut Bergonié, 229 Cours de l' Argonne, 33076 Bordeaux Cedex, France
| | - C Lervat
- Department of Pediatric Oncology, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - E Bogart
- Department of Methodology and Biostatistics, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - J P Meurant
- Department of Methodology and Biostatistics, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - S El Bedoui
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - G Decanter
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - K Hannebicque
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - C Regis
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - A Hamdani
- Department of Anesthesiology and Reanimation, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - N Penel
- Department of Medical Oncology, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - E Tresch-Bruneel
- Department of Methodology and Biostatistics, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| | - F Narducci
- Department of Oncologic Surgery, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Fréderic Combemale, BP 307, 59020 Lille Cedex, France
| |
Collapse
|
14
|
Regis C, Mesdag V, Tresch E, Chauvet MP, Boulanger L, Collinet P, Giard S. Abstract P2-13-09: Is nipple-sparing mastectomy with implant reconstruction for breast cancer safe and worthwhile? Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-13-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Nipple-sparing mastectomy (NSM) is a standard for bilateral prophylactic surgeries. However for cancer treatment, the preservation of the nipple areolar complex (NAC) is still discussed because of suspected increase of local recurrence and surgical specific complications as nipple or mastectomy flap necrosis. The aim of the study was to investigate both the relapse risk associated with NSM for breast cancer and women's satisfaction with preservation of the NAC.
Methods: We included retrospectively all patients who had skin-sparing mastectomy (SSM) or NSM from 2007 to 2012 for breast cancer or ductal carcinoma in situ (DCIS). We compared NSM and SSM group for oncological (overall survival (OS) and disease-free survival (DFS)) and surgical outcomes. Patients' satisfaction and quality of life has been evaluated by a specifically designed questionnaire, addressed by mail and inspired by the Breast-Q questionnaire with specific assessment of global esthetic result, harmony with the native breast and need for psychological support.
Results: During the study, we operated 5600 patients for a breast cancer, among them, 152 had NSM (n=63 / 41.5%) or SSM (n=89 / 58.5%) with immediate implant breast reconstruction. Eighty-nine (58.6%) patients had DCIS, and the other had invasive disease (86.9% of T1). The mastectomy has been indicated for primary cancer (81%) or recurrence (19%). The two groups did not differ significantly according to histological type (p=0.10), grade (p=0.84), hormonal receptor (p=0.7), HER2 (p=1.00), Ki67 (p=0.75) or node metastases (p=0.64). Median follow-up was 42 (IQR: 18-58 ) months. No cancer-related death occurred during the study. Local recurrence rate was 1.7% (n=1) in NSM group and 0% in SSM group (p=0.35). The recurrence did not appear on the preserved nipple. Severe complication requiring surgery (Grade 3 of Clavien-Dindo classification) occurred in 9.9% of the cases. In the NSM group, one patient had complete NAC necrosis and three patients suffered partial necrosis. Severe skin-flap necrosis leading to implant removal was more frequent in the SSM group (SSM: 6.7% (n=6) ; NSM: 0% (n=0); p=0.042). One hundred and four (80%) patients answered the questionnaire. Satisfaction about the aspect of the NAC was higher in the NSM group compared to SSM with delayed reconstruction of the nipple (75% vs 59%, p=0.14). Patients with NSM needed less psychological support before (p=0.028) and immediately after surgery (p=0.14) than patients in the SSM group, which may suggest a better acceptation of the surgery in this group.
Conclusion: NSM for breast cancer surgery was not associated with significant increase of local recurrence rate or surgical complications. Patient's satisfaction was high. Therefore, nipple-sparing mastectomy with immediate implant reconstruction can successfully and safely be performed for pre-invasive and small invasive breast cancer. Besides esthetic aspects, preserving the nipple may ease the acceptation of these radical surgeries.
Citation Format: Regis C, Mesdag V, Tresch E, Chauvet MP, Boulanger L, Collinet P, Giard S. Is nipple-sparing mastectomy with implant reconstruction for breast cancer safe and worthwhile?. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-13-09.
Collapse
Affiliation(s)
- C Regis
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| | - V Mesdag
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| | - E Tresch
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| | - MP Chauvet
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| | - L Boulanger
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| | - P Collinet
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| | - S Giard
- Centre Oscar Lambret, Lille, France; Biostatistics Unit, Centre Oscar Lambret, Lille, France; Hospital Jeanne de Flandre, University Hospital, Lille, France
| |
Collapse
|
15
|
Abe K, Hayato Y, Iida T, Ishihara K, Kameda J, Koshio Y, Minamino A, Mitsuda C, Miura M, Moriyama S, Nakahata M, Obayashi Y, Ogawa H, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takeuchi Y, Ueshima K, Watanabe H, Higuchi I, Ishihara C, Ishitsuka M, Kajita T, Kaneyuki K, Mitsuka G, Nakayama S, Nishino H, Okumura K, Saji C, Takenaga Y, Clark S, Desai S, Dufour F, Herfurth A, Kearns E, Likhoded S, Litos M, Raaf J, Stone J, Sulak L, Wang W, Goldhaber M, Casper D, Cravens J, Dunmore J, Griskevich J, Kropp W, Liu D, Mine S, Regis C, Smy M, Sobel H, Vagins M, Ganezer K, Hartfiel B, Hill J, Keig W, Jang J, Jeoung I, Kim J, Lim I, Scholberg K, Tanimoto N, Walter C, Wendell R, Ellsworth R, Tasaka S, Guillian G, Learned J, Matsuno S, Messier M, Ichikawa A, Ishida T, Ishii T, Iwashita T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Nitta K, Oyama Y, Suzuki A, Hasegawa M, Maesaka H, Nakaya T, Sasaki T, Sato H, Tanaka H, Yamamoto S, Yokoyama M, Haines T, Dazeley S, Hatakeyama S, Svoboda R, Sullivan G, Gran R, Habig A, Fukuda Y, Itow Y, Koike T, Jung C, Kato T, Kobayashi K, McGrew C, Sarrat A, Terri R, Yanagisawa C, Tamura N, Ikeda M, Sakuda M, Kuno Y, Yoshida M, Kim S, Yang B, Ishizuka T, Okazawa H, Choi Y, Seo H, Gando Y, Hasegawa T, Inoue K, Ishii H, Nishijima K, Ishino H, Watanabe Y, Koshiba M, Totsuka Y, Chen S, Deng Z, Liu Y, Kielczewska D, Berns H, Shiraishi K, Thrane E, Washburn K, Wilkes R. Search forn−n¯oscillation in Super-Kamiokande. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.91.072006] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
16
|
Abe K, Hayato Y, Iida T, Iyogi K, Kameda J, Koshio Y, Kozuma Y, Marti L, Miura M, Moriyama S, Nakahata M, Nakayama S, Obayashi Y, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takenaga Y, Ueno K, Ueshima K, Yamada S, Yokozawa T, Ishihara C, Kaji H, Kajita T, Kaneyuki K, Lee KP, McLachlan T, Okumura K, Shimizu Y, Tanimoto N, Labarga L, Kearns E, Litos M, Raaf JL, Stone JL, Sulak LR, Goldhaber M, Bays K, Kropp WR, Mine S, Regis C, Renshaw A, Smy MB, Sobel HW, Ganezer KS, Hill J, Keig WE, Jang JS, Kim JY, Lim IT, Albert JB, Scholberg K, Walter CW, Wendell R, Wongjirad TM, Ishizuka T, Tasaka S, Learned JG, Matsuno S, Smith SN, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Suzuki AT, Takeuchi Y, Ikeda M, Minamino A, Nakaya T, Fukuda Y, Itow Y, Mitsuka G, Tanaka T, Jung CK, Lopez GD, Taylor I, Yanagisawa C, Ishino H, Kibayashi A, Mino S, Mori T, Sakuda M, Toyota H, Kuno Y, Yoshida M, Kim SB, Yang BS, Okazawa H, Choi Y, Nishijima K, Koshiba M, Yokoyama M, Totsuka Y, Martens K, Schuemann J, Vagins MR, Chen S, Heng Y, Yang Z, Zhang H, Kielczewska D, Mijakowski P, Connolly K, Dziomba M, Thrane E, Wilkes RJ. Search for nucleon decay via n→ν[over ¯]π0 and p→ν[over ¯]π+ in Super-Kamiokande. Phys Rev Lett 2014; 113:121802. [PMID: 25279622 DOI: 10.1103/physrevlett.113.121802] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Indexed: 06/03/2023]
Abstract
We present the results of searches for nucleon decay via n→ν[over ¯]π0 and p→ν[over ¯]π+ using data from a combined 172.8 kt·yr exposure of Super-Kamiokande-I,-II, and-III. We set lower limits on the partial lifetime for each of these modes: τn→ν[over ¯]π0>1.1×10(33) years and τp→ν[over ¯]π+>3.9×10(32) years at a 90% confidence level.
Collapse
Affiliation(s)
- K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Hayato
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - T Iida
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Iyogi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - J Kameda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Koshio
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Kozuma
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Ll Marti
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - M Miura
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Nakahata
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - S Nakayama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Obayashi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - H Sekiya
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Shiozawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Suzuki
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Takenaga
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Ueno
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Ueshima
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - S Yamada
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - T Yokozawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - C Ishihara
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - H Kaji
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T Kajita
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K Kaneyuki
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K P Lee
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T McLachlan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Okumura
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Shimizu
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - N Tanimoto
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - L Labarga
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - E Kearns
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Litos
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - J L Raaf
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - J L Stone
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - L R Sulak
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - M Goldhaber
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Bays
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - W R Kropp
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - S Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - C Regis
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - A Renshaw
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - M B Smy
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - H W Sobel
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K S Ganezer
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - J Hill
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - W E Keig
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - J S Jang
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - J Y Kim
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - I T Lim
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - J B Albert
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina 27708, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - C W Walter
- Department of Physics, Duke University, Durham, North Carolina 27708, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - R Wendell
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - T M Wongjirad
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - T Ishizuka
- Junior College, Fukuoka Institute of Technology, Fukuoka 811-0214, Japan
| | - S Tasaka
- Information and Multimedia Center, Gifu University, Gifu, Gifu 501-1193, Japan
| | - J G Learned
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Matsuno
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S N Smith
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - A T Suzuki
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - Y Takeuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Ikeda
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - A Minamino
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - T Nakaya
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Miyagi 980-0845, Japan
| | - Y Itow
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan and Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - G Mitsuka
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - T Tanaka
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - C K Jung
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - G D Lopez
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - I Taylor
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - C Yanagisawa
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - H Ishino
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - A Kibayashi
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - S Mino
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - T Mori
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - M Sakuda
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - H Toyota
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - Y Kuno
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Yoshida
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S B Kim
- Department of Physics, Seoul National University, Seoul 151-742, Korea
| | - B S Yang
- Department of Physics, Seoul National University, Seoul 151-742, Korea
| | - H Okazawa
- Department of Informatics in Social Welfare, Shizuoka University of Welfare, Yaizu, Shizuoka, 425-8611, Japan
| | - Y Choi
- Department of Physics, Sungkyunkwan University, Suwon 440-746, Korea
| | - K Nishijima
- Department of Physics, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
| | - M Koshiba
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - M Yokoyama
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Totsuka
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - K Martens
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - J Schuemann
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M R Vagins
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA and Kavli Institute for the Physics and Mathematics of the Universe (WPI), Todai Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - S Chen
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - Y Heng
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - Z Yang
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - H Zhang
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - D Kielczewska
- Institute of Experimental Physics, Warsaw University, 00-681 Warsaw, Poland
| | - P Mijakowski
- Institute of Experimental Physics, Warsaw University, 00-681 Warsaw, Poland
| | - K Connolly
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - M Dziomba
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - E Thrane
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - R J Wilkes
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| |
Collapse
|
17
|
Litos M, Abe K, Hayato Y, Iida T, Ikeda M, Iyogi K, Kameda J, Kobayashi K, Koshio Y, Kozuma Y, Miura M, Moriyama S, Nakahata M, Nakayama S, Obayashi Y, Ogawa H, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takenaga Y, Takeuchi Y, Ueno K, Ueshima K, Watanabe H, Yamada S, Yokozawa T, Hazama S, Ishihara C, Kaji H, Kajita T, Kaneyuki K, McLachlan T, Okumura K, Shimizu Y, Tanimoto N, Vagins MR, Kearns E, Stone JL, Sulak LR, Dufour F, Raaf JL, Henning B, Goldhaber M, Bays K, Casper D, Cravens JP, Kropp WR, Mine S, Regis C, Smy MB, Sobel HW, Ganezer KS, Hill J, Keig WE, Jang JS, Kim JY, Lim IT, Albert JB, Wongjirad T, Wendell R, Scholberg K, Walter CW, Tasaka S, Learned JG, Matsuno S, Watanabe Y, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Nishino H, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Suzuki AT, Minamino A, Nakaya T, Fukuda Y, Itow Y, Mitsuka G, Tanaka T, Jung CK, Lopez G, McGrew C, Terri R, Yanagisawa C, Tamura N, Ishino H, Kibayashi A, Mino S, Mori T, Sakuda M, Toyota H, Kuno Y, Yoshida M, Kim SB, Yang BS, Ishizuka T, Okazawa H, Choi Y, Nishijima K, Yokosawa Y, Koshiba M, Yokoyama M, Totsuka Y, Chen S, Heng Y, Yang Z, Zhang H, Kielczewska D, Mijakowski P, Connolly K, Dziomba M, Thrane E, Wilkes RJ. Search for dinucleon decay into kaons in Super-Kamiokande. Phys Rev Lett 2014; 112:131803. [PMID: 24745406 DOI: 10.1103/physrevlett.112.131803] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Indexed: 06/03/2023]
Abstract
A search for the dinucleon decay pp → K+ K+ has been performed using 91.6 kton·yr data from Super-Kamiokande-I. This decay provides a sensitive probe of the R-parity-violating parameter λ112''. A boosted decision tree analysis found no signal candidates in the data. The expected background was 0.28±0.19 atmospheric neutrino induced events and the estimated signal detection efficiency was 12.6%±3.2%. A lower limit of 1.7×10(32) years has been placed on the partial lifetime of the decay O16 → C14K+ K+ at 90% C.L. A corresponding upper limit of 7.8×10(-9) has been placed on the parameter λ112''.
Collapse
Affiliation(s)
- M Litos
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Hayato
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - T Iida
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - M Ikeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Iyogi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - J Kameda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Kobayashi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Koshio
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Kozuma
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - M Miura
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Nakahata
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - S Nakayama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Obayashi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - H Ogawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - H Sekiya
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - M Shiozawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - Y Suzuki
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Takenaga
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - Y Takeuchi
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K Ueno
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - K Ueshima
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - H Watanabe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - S Yamada
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - T Yokozawa
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | - S Hazama
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - C Ishihara
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - H Kaji
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T Kajita
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Kaneyuki
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - T McLachlan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - K Okumura
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - Y Shimizu
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - N Tanimoto
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | - M R Vagins
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - E Kearns
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - J L Stone
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA and Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - L R Sulak
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - F Dufour
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - J L Raaf
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - B Henning
- Department of Physics, Boston University, Boston, Massachusetts 02215, USA
| | - M Goldhaber
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Bays
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - D Casper
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - J P Cravens
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - W R Kropp
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - S Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - C Regis
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - M B Smy
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - H W Sobel
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697-4575, USA
| | - K S Ganezer
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - J Hill
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - W E Keig
- Department of Physics, California State University, Dominguez Hills, Carson, California 90747, USA
| | - J S Jang
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - J Y Kim
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - I T Lim
- Department of Physics, Chonnam National University, Kwangju 500-757, Korea
| | - J B Albert
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - T Wongjirad
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - R Wendell
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - K Scholberg
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - C W Walter
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - S Tasaka
- Department of Physics, Gifu University, Gifu, Gifu 501-1193, Japan
| | - J G Learned
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Matsuno
- Department of Physics and Astronomy, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - Y Watanabe
- Physics Division, Department of Engineering, Kanagawa University, Kanagawa, Yokohama 221-8686, Japan
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Nakamura
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Nishino
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - A T Suzuki
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Minamino
- Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - T Nakaya
- Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa, Chiba 277-8583, Japan and Department of Physics, Kyoto University, Kyoto, Kyoto 606-8502, Japan
| | - Y Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Miyagi 980-0845, Japan
| | - Y Itow
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - G Mitsuka
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - T Tanaka
- Solar Terrestrial Environment Laboratory, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - C K Jung
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - G Lopez
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - C McGrew
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - R Terri
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - C Yanagisawa
- Department of Physics and Astronomy, State University of New York, Stony Brook, New York 11794-3800, USA
| | - N Tamura
- Department of Physics, Niigata University, Niigata, Niigata 950-2181, Japan
| | - H Ishino
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - A Kibayashi
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - S Mino
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - T Mori
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - M Sakuda
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - H Toyota
- Department of Physics, Okayama University, Okayama, Okayama 700-8530, Japan
| | - Y Kuno
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Yoshida
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S B Kim
- Department of Physics, Seoul National University, Seoul 151-742, Korea
| | - B S Yang
- Department of Physics, Seoul National University, Seoul 151-742, Korea
| | - T Ishizuka
- Department of Systems Engineering, Shizuoka University, Hamamatsu, Shizuoka 432-8561, Japan
| | - H Okazawa
- Department of Informatics in Social Welfare, Shizuoka University of Welfare, Yaizu, Shizuoka 425-8611, Japan
| | - Y Choi
- Department of Physics, Sungkyunkwan University, Suwon 440-746, Korea
| | - K Nishijima
- Department of Physics, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
| | - Y Yokosawa
- Department of Physics, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan
| | - M Koshiba
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - M Yokoyama
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Totsuka
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - S Chen
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - Y Heng
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - Z Yang
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - H Zhang
- Department of Engineering Physics, Tsinghua University, Beijing 100084, China
| | - D Kielczewska
- Institute of Experimental Physics, Warsaw University, 00-681 Warsaw, Poland
| | - P Mijakowski
- Institute of Experimental Physics, Warsaw University, 00-681 Warsaw, Poland
| | - K Connolly
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - M Dziomba
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - E Thrane
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| | - R J Wilkes
- Department of Physics, University of Washington, Seattle, Washington 98195-1560, USA
| |
Collapse
|
18
|
Eibach D, Casalegno JS, Bouscambert M, Bénet T, Regis C, Comte B, Kim BA, Vanhems P, Lina B. Routes of transmission during a nosocomial influenza A(H3N2) outbreak among geriatric patients and healthcare workers. J Hosp Infect 2014; 86:188-93. [PMID: 24468292 DOI: 10.1016/j.jhin.2013.11.009] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Accepted: 11/20/2013] [Indexed: 10/25/2022]
Abstract
BACKGROUND Influenza presents a life-threatening infection for hospitalized geriatric patients, who might be nosocomially infected via healthcare workers (HCWs), other patients or visitors. In the 2011/2012 influenza season an influenza A(H3N2) outbreak occurred in the geriatric department at the Hôpital Edouard Herriot, Lyon. AIM To clarify the transmission chain for this influenza A(H3N2) outbreak by sequence analysis and to identify preventive measures. METHODS Laboratory testing of patients with influenza-like illness in the acute care geriatric department revealed 22 cases of influenza between 19th February and 15th March 2012. Incidences for patients and HCWs were calculated and possible epidemiological links were analysed using a questionnaire. Neuraminidase and haemagglutinin genes of culture-positive samples and community influenza samples were sequenced and clustered to detect patients with identical viral strains. FINDINGS Sixteen patients and six HCWs were affected, resulting in an attack rate of 24% and 11% respectively. Six nosocomial infections were recorded. The sequence analysis confirmed three independent influenza clusters on three different sections of the geriatric ward. For at least two clusters, an HCW source was determined. CONCLUSION Epidemiological and microbiological results confirm influenza transmission from HCWs to patients. A higher vaccination rate, isolation measures and better hand hygiene are recommended in order to prevent outbreaks in future influenza seasons.
Collapse
Affiliation(s)
- D Eibach
- Virology Department, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France; European Public Health Microbiology Training Programme (EUPHEM), European Centre for Disease Prevention and Control, Stockholm, Sweden.
| | - J-S Casalegno
- Virology Department, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - M Bouscambert
- Virology Department, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - T Bénet
- Infection Control and Epidemiology Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France; Epidemiology and Public Health Group, CNRS UMR 5558, University of Lyon 1, Lyon, France
| | - C Regis
- Infection Control and Epidemiology Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France; Epidemiology and Public Health Group, CNRS UMR 5558, University of Lyon 1, Lyon, France
| | - B Comte
- PAM de gériatrie, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - B-A Kim
- PAM de gériatrie, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - P Vanhems
- Infection Control and Epidemiology Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France; Epidemiology and Public Health Group, CNRS UMR 5558, University of Lyon 1, Lyon, France
| | - B Lina
- Virology Department, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
19
|
Abe K, Hayato Y, Iida T, Iyogi K, Kameda J, Koshio Y, Kozuma Y, Marti L, Miura M, Moriyama S, Nakahata M, Nakayama S, Obayashi Y, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takenaga Y, Ueno K, Ueshima K, Yamada S, Yokozawa T, Ishihara C, Kaji H, Kajita T, Kaneyuki K, Lee KP, McLachlan T, Okumura K, Shimizu Y, Tanimoto N, Labarga L, Kearns E, Litos M, Raaf JL, Stone JL, Sulak LR, Goldhaber M, Bays K, Kropp WR, Mine S, Regis C, Renshaw A, Smy MB, Sobel HW, Ganezer KS, Hill J, Keig WE, Jang JS, Kim JY, Lim IT, Albert JB, Scholberg K, Walter CW, Wendell R, Wongjirad TM, Ishizuka T, Tasaka S, Learned JG, Matsuno S, Smith SN, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Suzuki AT, Takeuchi Y, Ikeda M, Minamino A, Nakaya T, Fukuda Y, Itow Y, Mitsuka G, Tanaka T, Jung CK, Lopez GD, Taylor I, Yanagisawa C, Ishino H, Kibayashi A, Mino S, Mori T, Sakuda M, Toyota H, Kuno Y, Yoshida M, Kim SB, Yang BS, Okazawa H, Choi Y, Nishijima K, Koshiba M, Yokoyama M, Totsuka Y, Martens K, Schuemann J, Vagins MR, Chen S, Heng Y, Yang Z, Zhang H, Kielczewska D, Mijakowski P, Connolly K, Dziomba M, Thrane E, Wilkes RJ. Evidence for the appearance of atmospheric tau neutrinos in super-Kamiokande. Phys Rev Lett 2013; 110:181802. [PMID: 23683190 DOI: 10.1103/physrevlett.110.181802] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Indexed: 06/02/2023]
Abstract
Super-Kamiokande atmospheric neutrino data were fit with an unbinned maximum likelihood method to search for the appearance of tau leptons resulting from the interactions of oscillation-generated tau neutrinos in the detector. Relative to the expectation of unity, the tau normalization is found to be 1.42 ± 0.35(stat)(-0.12)(+0.14)(syst) excluding the no-tau-appearance hypothesis, for which the normalization would be zero, at the 3.8σ level. We estimate that 180.1 ± 44.3(stat)(-15.2)(+17.8) (syst) tau leptons were produced in the 22.5 kton fiducial volume of the detector by tau neutrinos during the 2806 day running period. In future analyses, this large sample of selected tau events will allow the study of charged current tau neutrino interaction physics with oscillation produced tau neutrinos.
Collapse
Affiliation(s)
- K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abe K, Hayato Y, Iida T, Ikeda M, Iyogi K, Kameda J, Koshio Y, Kozuma Y, Miura M, Moriyama S, Nakahata M, Nakayama S, Obayashi Y, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takenaga Y, Takeuchi Y, Ueno K, Ueshima K, Watanabe H, Yamada S, Yokozawa T, Ishihara C, Kaji H, Lee KP, Kajita T, Kaneyuki K, McLachlan T, Okumura K, Shimizu Y, Tanimoto N, Martens K, Vagins MR, Labarga L, Magro LM, Dufour F, Kearns E, Litos M, Raaf JL, Stone JL, Sulak LR, Goldhaber M, Bays K, Kropp WR, Mine S, Regis C, Smy MB, Sobel HW, Ganezer KS, Hill J, Keig WE, Jang JS, Kim JY, Lim IT, Albert JB, Scholberg K, Walter CW, Wendell R, Wongjirad TM, Tasaka S, Learned JG, Matsuno S, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Nishino H, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Suzuki AT, Minamino A, Nakaya T, Fukuda Y, Itow Y, Mitsuka G, Tanaka T, Jung CK, Taylor I, Yanagisawa C, Ishino H, Kibayashi A, Mino S, Mori T, Sakuda M, Toyota H, Kuno Y, Kim SB, Yang BS, Ishizuka T, Okazawa H, Choi Y, Nishijima K, Koshiba M, Yokoyama M, Totsuka Y, Chen S, Heng Y, Yang Z, Zhang H, Kielczewska D, Mijakowski P, Connolly K, Dziomba M, Wilkes RJ. Search for differences in oscillation parameters for atmospheric neutrinos and antineutrinos at Super-Kamiokande. Phys Rev Lett 2011; 107:241801. [PMID: 22242990 DOI: 10.1103/physrevlett.107.241801] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2011] [Indexed: 05/31/2023]
Abstract
We present a search for differences in the oscillations of antineutrinos and neutrinos in the Super-Kamiokande-I, -II, and -III atmospheric neutrino sample. Under a two-flavor disappearance model with separate mixing parameters between neutrinos and antineutrinos, we find no evidence for a difference in oscillation parameters. Best-fit antineutrino mixing is found to be at (Δm2,sin2 2θ)=(2.0×10(-3) eV2, 1.0) and is consistent with the overall Super-K measurement.
Collapse
Affiliation(s)
- K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Nishino H, Clark S, Abe K, Hayato Y, Iida T, Ikeda M, Kameda J, Kobayashi K, Koshio Y, Miura M, Moriyama S, Nakahata M, Nakayama S, Obayashi Y, Ogawa H, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takenaga Y, Takeuchi Y, Ueno K, Ueshima K, Watanabe H, Yamada S, Hazama S, Higuchi I, Ishihara C, Kajita T, Kaneyuki K, Mitsuka G, Okumura K, Tanimoto N, Vagins MR, Dufour F, Kearns E, Litos M, Raaf JL, Stone JL, Sulak LR, Wang W, Goldhaber M, Dazeley S, Svoboda R, Bays K, Casper D, Cravens JP, Kropp WR, Mine S, Regis C, Smy MB, Sobel HW, Ganezer KS, Hill J, Keig WE, Jang JS, Kim JY, Lim IT, Fechner M, Scholberg K, Walter CW, Wendell R, Tasaka S, Learned JG, Matsuno S, Watanabe Y, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Suzuki AT, Minamino A, Nakaya T, Yokoyama M, Fukuda Y, Itow Y, Tanaka T, Jung CK, Lopez G, McGrew C, Terri R, Yanagisawa C, Tamura N, Idehara Y, Sakuda M, Kuno Y, Yoshida M, Kim SB, Yang BS, Ishizuka T, Okazawa H, Choi Y, Seo HK, Furuse Y, Nishijima K, Yokosawa Y, Koshiba M, Totsuka Y, Chen S, Heng Y, Yang Z, Zhang H, Kielczewska D, Thrane E, Wilkes RJ. Search for proton decay via p-->e+pi0 and p-->micro+pi0 in a large water Cherenkov detector. Phys Rev Lett 2009; 102:141801. [PMID: 19392425 DOI: 10.1103/physrevlett.102.141801] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2009] [Indexed: 05/27/2023]
Abstract
We have searched for proton decays via p-->e;{+}pi;{0} and p-->micro;{+}pi;{0} using data from a 91.7 kt.yr exposure of Super-Kamiokande-I and a 49.2 kt.yr exposure of Super-Kamiokande-II. No candidate events were observed with expected backgrounds induced by atmospheric neutrinos of 0.3 events for each decay mode. From these results, we set lower limits on the partial lifetime of 8.2 x 10;{33} and 6.6 x 10;{33} years at 90% confidence level for p-->e;{+}pi;{0} and p-->micro;{+}pi;{0} modes, respectively.
Collapse
Affiliation(s)
- H Nishino
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Chiba 277-8582, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abe K, Hayato Y, Iida T, Ikeda M, Kameda J, Koshio Y, Minamino A, Miura M, Moriyama S, Nakahata M, Nakayama S, Obayashi Y, Ogawa H, Sekiya H, Shiozawa M, Suzuki Y, Takeda A, Takeuchi Y, Ueshima K, Watanabe H, Yamada S, Higuchi I, Ishihara C, Kajita T, Kaneyuki K, Mitsuka G, Nishino H, Okumura K, Saji C, Takenaga Y, Clark S, Desai S, Dufour F, Kearns E, Likhoded S, Litos M, Raaf JL, Stone JL, Sulak LR, Wang W, Goldhaber M, Casper D, Cravens JP, Dunmore J, Kropp WR, Liu DW, Mine S, Regis C, Smy MB, Sobel HW, Vagins MR, Ganezer KS, Hartfield B, Hill J, Keig WE, Jang JS, Jeong IS, Kim JY, Lim IT, Scholberg K, Fechner M, Tanimoto N, Walter CW, Wendell R, Tasaka S, Guillian G, Learned JG, Matsuno S, Messier MD, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Nishikawa K, Oyama Y, Totsuka Y, Suzuki AT, Nakaya T, Tanaka H, Yokoyama M, Haines TJ, Dazeley S, Svoboda R, Habig A, Fukuda Y, Sato T, Itow Y, Koike T, Tanaka T, Jung CK, Kato T, Kobayashi K, McGrew C, Sarrat A, Terri R, Yanagisawa C, Tamura N, Idehara Y, Sakuda M, Sugihara M, Kuno Y, Yoshida M, Kim SB, Yang BS, Ishizuka T, Okazawa H, Choi Y, Seo HK, Gando Y, Inoue K, Furuse Y, Ishii H, Nishijima K, Watanabe Y, Koshiba M, Chen S, Deng Z, Liu Y, Kielczewska D, Berns H, Shiraishi KK, Thrane E, Wilkes RJ. Search for matter-dependent atmospheric neutrino oscillations in Super-Kamiokande. Int J Clin Exp Med 2008. [DOI: 10.1103/physrevd.77.052001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
23
|
Abe K, Hayato Y, Iida T, Ishihara K, Kameda J, Koshio Y, Minamino A, Mitsuda C, Miura M, Moriyama S, Nakahata M, Obayashi Y, Ogawa H, Shiozawa M, Suzuki Y, Takeda A, Takeuchi Y, Ueshima K, Higuchi I, Ishihara C, Ishitsuka M, Kajita T, Kaneyuki K, Mitsuka G, Nakayama S, Nishino H, Okumura K, Saji C, Takenaga Y, Totsuka Y, Clark S, Desai S, Dufour F, Kearns E, Likhoded S, Litos M, Raaf JL, Stone JL, Sulak LR, Wang W, Goldhaber M, Casper D, Cravens JP, Kropp WR, Liu DW, Mine S, Regis C, Smy MB, Sobel HW, Vagins MR, Ganezer KS, Hill JE, Keig WE, Jang JS, Kim JY, Lim IT, Scholberg K, Tanimoto N, Walter CW, Wendell R, Ellsworth RW, Tasaka S, Guillian E, Learned JG, Matsuno S, Messier MD, Ichikawa AK, Ishida T, Ishii T, Iwashita T, Kobayashi T, Nakadaira T, Nakamura K, Nitta K, Oyama Y, Suzuki AT, Hasegawa M, Kato I, Maesaka H, Nakaya T, Nishikawa K, Sasaki T, Sato H, Yamamoto S, Yokoyama M, Haines TJ, Dazeley S, Hatakeyama S, Svoboda R, Sullivan GW, Habig A, Gran R, Fukuda Y, Sato T, Itow Y, Koike T, Jung CK, Kato T, Kobayashi K, Malek M, McGrew C, Sarrat A, Terri R, Yanagisawa C, Tamura N, Sakuda M, Sugihara M, Kuno Y, Yoshida M, Kim SB, Yoo J, Ishizuka T, Okazawa H, Choi Y, Seo HK, Gando Y, Hasegawa T, Inoue K, Ishii H, Nishijima K, Ishino H, Watanabe Y, Koshiba M, Kielczewska D, Zalipska J, Berns HG, Shiraishi KK, Washburn K, Wilkes RJ. Measurement of atmospheric neutrino flux consistent with tau neutrino appearance. Phys Rev Lett 2006; 97:171801. [PMID: 17155460 DOI: 10.1103/physrevlett.97.171801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2006] [Indexed: 05/12/2023]
Abstract
A search for the appearance of tau neutrinos from nu(mu) <--> nu(tau) oscillations in the atmospheric neutrinos has been performed using 1489.2 days of atmospheric neutrino data from the Super-Kamiokande-I experiment. A best fit tau neutrino appearance signal of 138+/-48(stat)-32(+15)(syst) events is obtained with an expectation of 78+/-26(syst). The hypothesis of no tau neutrino appearance is disfavored by 2.4 sigma.
Collapse
Affiliation(s)
- K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Gifu 506-1205, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Regis C, Taieb S, Lesoin A, Baranzelli MC, Blehaut T, Leblanc E. Présentation inhabituelle d'un choriocarcinome gestationnel. ACTA ACUST UNITED AC 2006; 34:716-9. [PMID: 16971152 DOI: 10.1016/j.gyobfe.2006.05.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2006] [Accepted: 05/02/2006] [Indexed: 10/24/2022]
Abstract
Gestational choriocarcinoma is a rare malignant tumour with a strong metastatic potential. We report a case of a 31-year-old patient with a gestational trophoblastic tumor revealed by renal and pulmonary metastases, one year after a normal pregnancy. The diagnosis was established by the pathologist on the radical nephrectomy specimen. The evolution was quickly favorable after adequate treatment using multiagent chemotherapy. This case highlights the polymorphic aspects of the gestational choriocarcinoma and stresses the importance of a betaHCG assessment anytime abnormal symptoms occur in the outcome of a pregnancy.
Collapse
Affiliation(s)
- C Regis
- Service de cancérologie gynécologique, centre de lutte contre le cancer (CLCC) Oscar-Lambret, BP 307, 3, rue Frédéric-Combemale, 59020 Lille cedex, France
| | | | | | | | | | | |
Collapse
|
25
|
Collinet P, Marcelli F, Villers A, Regis C, Lucot JP, Cosson M, Vinatier D. Prise en charge de l'endométriose urinaire. ACTA ACUST UNITED AC 2006; 34:347-52. [PMID: 16580867 DOI: 10.1016/j.gyobfe.2006.02.014] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2005] [Accepted: 02/14/2006] [Indexed: 11/24/2022]
Abstract
Endometriosis of the urinary tract (bladder and/or ureter) is rare and concerns 1-2% of cases of endometriosis. Surgical management is usually mandatory. Rate of peri operative morbidity is low. There is a risk of functional (dysuria, chronic hypogastric pains, imperiosity) and anatomical recurrences (0-15 and 0-10% respectively). Surgical treatment of bladder and/or ureteral endometriosis requires informed consent of patients and multidisciplinary management.
Collapse
Affiliation(s)
- P Collinet
- Clinique de Gynécologie, Obstétrique et Néonatalogie, Hôpital Jeanne-de-Flandre, CHRU de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France.
| | | | | | | | | | | | | |
Collapse
|
26
|
Trabaud MA, Leriche-Guerin K, Regis C, Bordes I, Cotte L, Detmer J, Kolberg J, Ritter J, Trépo C. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus. J Med Virol 2000; 61:352-9. [PMID: 10861645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The presence of primary zidovudine (AZT)-resistance (mutation T215Y/F) or lamivudine (3TC)-resistance (mutation M184V) was evaluated in 90 drug-naive patients infected with human immunodeficiency virus type-1 (HIV-1) between 1987 and 1997. The proportion of mutant strains in proviral samples or plasma viral samples was determined using a differential hybridization assay. Mutation T215Y/F was found in five (5.6%) patients infected between 1994 and 1997, whereas none of these patients harbored the mutation M184V. The T215Y/F mutation was present in the virus and/or provirus and persisted for at least two years. In one patient, the mutant provirus was associated with only wild-type free virus. Four of these patients were followed, and two were treated subsequently to a regimen containing AZT but with low response. The persistence of primary resistance mutations might depend on the proportion of these mutations at the time of infection, although mutant provirus might not give rise to replicating variants.
Collapse
Affiliation(s)
- M A Trabaud
- Laboratoire d'Hygiène et d'immunologie, Faculté de Médecine, Lyon, France.
| | | | | | | | | | | | | | | | | |
Collapse
|